Phase II trial of didemnin-B in advanced epithelial ovarian cancer - A Southwest Oncology Group Study

Joanna M. Cain, P. Y. Liu, David E. Alberts, Holly H. Gallion, Leslie Laufman, Janet O'Sullivan, Geoffrey Weiss, John N. Bickers

Research output: Contribution to journalArticle

18 Scopus citations

Abstract

A Phase II study of Didemnin-B, a marine cyclic depsipeptide, was undertaken in patients with progressive epithelial ovarian cancer. The starting dose was 2.6 mg/m2. Fifteen patients received the drug, of whom twelve were evaluable. There were no responses observed in the twelve patients. The two most frequent toxicities were nausea and vomiting and anemia. On the basis of this trial, Didemnin-B is not felt to have significant effect with epithelial ovarian cancer.

Original languageEnglish (US)
Pages (from-to)23-24
Number of pages2
JournalInvestigational New Drugs
Volume10
Issue number1
DOIs
StatePublished - Mar 1 1992

Keywords

  • Didemnin-B
  • ovarian cancer

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Phase II trial of didemnin-B in advanced epithelial ovarian cancer - A Southwest Oncology Group Study'. Together they form a unique fingerprint.

  • Cite this

    Cain, J. M., Liu, P. Y., Alberts, D. E., Gallion, H. H., Laufman, L., O'Sullivan, J., Weiss, G., & Bickers, J. N. (1992). Phase II trial of didemnin-B in advanced epithelial ovarian cancer - A Southwest Oncology Group Study. Investigational New Drugs, 10(1), 23-24. https://doi.org/10.1007/BF01275473